By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. We conducted a phase 3, ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Gilead Sciences withdrew Trodelvy's FDA accelerated approval for urothelial cancer after the TROPiCS-04 study failed to meet the primary endpoint of overall survival. The TROPiCS-04 study showed ...

"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...

Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Sarcopenia as a ...

Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus pembrolizumab ...